MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma

Gynecologic Oncology

Volumn 100, Issue 2, 2006, Pages 239-246

  Guminski, Alexander D ^a,b   Balleine, Rosemary L ^a,b   Chiew, Yoke Eng ^a,b   Webster, Lucy R ^a,b   Tapner, Michael ^b   Farrell, Geoffrey C ^b   Harnett, Paul R ^a,b   DeFazio, Anna ^a,b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

Drug resistance; Drug transporters; Platinum based chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; MULTIDRUG RESISTANCE PROTEIN 2; PACLITAXEL;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG SENSITIVITY; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CULTURE; MALE; NONHUMAN; OVARY CARCINOMA; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OVARIAN NEOPLASMS; RATS; RATS, WISTAR;

EID: 30444454344     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.08.046     Document Type: Article

References (36)

1. L.H. Einhorn Curing metastatic testicular cancer Proc. Natl. Acad. Sci. U. S. A. 99 2002 4592 4595
2. A.D. Guminski, P.R. Harnett, and A. deFazio Scientists and clinicians test their metal-back to the future with platinum compounds Lancet Oncol. 3 2002 312 318
3. S.C. Mann, P.A. Andrews, and S.B. Howell Short-term cis- diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells Cancer Chemother. Pharmacol. 25 1990 236 240
4. S.Y. Loh, P. Mistry, L.R. Kelland, G. Abel, and K.R. Harrap Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes Br. J. Cancer 66 1992 1109 1115
5. M.M. Gottesman, and S.V. Ambudkar Overview: ABC transporters and human disease J. Bioenerg. Biomembr. 33 2001 453 458
6. N. Kartner, M. Shales, J.R. Riordan, and V. Ling Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein Cancer Res. 43 1983 4413 4419
7. S.P. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, and K.C. Almquist Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650 1654
8. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J. Natl. Cancer Inst. 92 2000 1295 1302
9. K. Taniguchi, M. Wada, K. Kohno, T. Nakamura, T. Kawabe, and M. Kawakami A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation Cancer Res. 56 1996 4124 4129
10. R.F. Ozols Pharmacologic reversal of drug resistance in ovarian cancer Semin. Oncol. 12 1985 7 11
11. M. Kool, M. de Haas, G.L. Scheffer, R.J. Scheper, M.J. van Eijk, and J.A. Juijn Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines Cancer Res. 57 1997 3537 3547
12. B. Liedert, V. Materna, D. Schadendorf, J. Thomale, and H. Lage Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin J. Invest. Dermatol. 121 2003 172 176
13. Y. Cui, J. Konig, J.K. Buchholz, H. Spring, I. Leier, and D. Keppler Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells Mol. Pharmacol. 55 1999 929 937
14. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev., Cancer 2 2002 48 58
15. A.F. List, K.J. Kopecky, C.L. Willman, D.R. Head, D.L. Persons, and M.L. Slovak Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study Blood 98 2001 3212 3220
16. C.C. Paulusma, P.J. Bosma, G.J. Zaman, C.T. Bakker, M. Otter, and G.L. Scheffer Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene Science 271 1996 1126 1128
17. H.K. Kleinman, M.L. McGarvey, J.R. Hassell, V.L. Star, F.B. Cannon, and G.W. Laurie Basement membrane complexes with biological activity Biochemistry 25 1986 312 318
18. M. Tapner, C. Liddle, B. Goodwin, J. George, and G.C. Farrell Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes Hepatology 24 1996 367 373
19. S.A. Cannistra Paclitaxel in ovarian cancer: how can we make it better? J. Clin. Oncol. 12 1994 1743 1744
20. G.L. Scheffer, M. Kool, M. Heijn, M. de Haas, A.C. Pijnenborg, and J. Wijnholds Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies Cancer Res. 60 2000 5269 5277
21. M.G. Donner, and D. Keppler Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver Hepatology 34 2001 351 359
22. C.C. Paulusma, M.A. van Geer, R. Evers, M. Heijn, R. Ottenhoff, and P. Borst Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione Biochem. J. 338 1999 393 401
23. L. van Zuylen, J. Verweij, K. Nooter, E. Brouwer, G. Stoter, and A. Sparreboom Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans Clin Cancer Res. 6 2000 2598 2603
24. T.P. Schaub, J. Kartenbeck, J. Konig, H. Spring, J. Dorsam, and G. Staehler Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma J. Am. Soc. Nephrol. 10 1999 1159 1169
25. A.T. Nies, J. Konig, M. Pfannschmidt, E. Klar, W.J. Hofmann, and D. Keppler Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma Int. J. Cancer 94 2001 492 499
26. G.E. Sandusky, K.S. Mintze, S.E. Pratt, and A.H. Dantzig Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays Histopathology 41 2002 65 74
27. H.J. Arts, D. Katsaros, E.G. de Vries, M. Massobrio, F. Genta, and S. Danese Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma Clin. Cancer Res. 5 1999 2798 2805
28. V. Materna, J. Pleger, U. Hoffmann, and H. Lage RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response Gynecol. Oncol. 94 2004 152 160
29. S. Kamazawa, J. Kigawa, Y. Kanamori, H. Itamochi, S. Sato, and T. Iba Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer Gynecol. Oncol. 86 2002 171 176
30. F. Mayer, H. Stoop, G.L. Scheffer, R. Scheper, J.W. Oosterhuis, and L.H. Looijenga Molecular determinants of treatment response in human germ cell tumors Clin. Cancer Res. 9 2003 767 773
31. M.J. Harris, M. Kuwano, M. Webb, and P.G. Board Identification of the apical membrane-targeting signal of the multidrug resistance-associated protein 2 (MRP2/MOAT) J. Biol. Chem. 276 2001 20876 20881
32. M. Hirouchi, H. Suzuki, M. Itoda, S. Ozawa, J. Sawada, and I. Ieiri Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2 Pharm. Res. 21 2004 742 778
33. T. Kawabe, Z.S. Chen, M. Wada, T. Uchiumi, M. Ono, and S. Akiyama Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2) FEBS Lett. 456 1999 327 331
34. R. Evers, M. Kool, L. van Deemter, H. Janssen, J. Calafat, and L.C. Oomen Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA J. Clin. Invest. 101 1998 1310 1319
35. X.J. Liang, D.W. Shen, S. Garfield, and M.M. Gottesman Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines Cancer Res. 63 2003 5909 5916
36. R. Safaei, K. Katano, B.J. Larson, G. Samimi, A.K. Holzer, and W. Naerdemann Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells Clin. Cancer Res. 11 2005 756 767